Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis

Open access
Hu, Shanshan, Su, Xiaorong, Fan, Guorong · 2023 · Diabetology & Metabolic Syndrome

Abstract

Objectives: To update and assess the efficacy and tolerability of once weekly subcutaneous semaglutide in patients with type 2 diabetes (T2D). Materials and methods: PubMed, Science Direct, Cochrane Library, Clinical trial, Springer, OVID, China National Knowledge Infrastructure (CNKI), WanFang Data and China Science and Technology Journal Database (VIP) were searched from inception to January 18, 2023. Randomized controlled trials (RCTs) comparing subcutaneous semaglutide with placebo or any other antidiabetic agent in adults with T2D were eligible. The risk ratio (RR) and mean difference (MD) with 95% confidence intervals (CIs) were determined to synthesize the results. Results: A total of 17 trials enrolling 14,940 T2D patients were included. For efficacy, compared with placebo, semaglutide exhibited beneficial effects on glycosylated hemoglobin A1c (HbA1c) control [MD -0.97%, 95% CI (-1.33, -0.62), I2 = 91%; MD -1.36%, 95% CI (-1.59, -1.13), I2 = 84%, semaglutide 0.5 and 1.0 mg, respectively], body weight reduction, blood pressure control. At the same time, subcutaneous semaglutide 0.5 and 1 mg reduced HbA 1c by 0.56% (95% CI 0.32 to 0.80) and 0.63% (95% CI 0.35 to 0.91) compared to other glucose-lowering agents. For tolerability, semaglutide did not increase the incidence of adverse events (AEs) and serious adverse events (SAEs), severe or blood glucose (BG) confirmed hypoglycaemia, acute pancreatitis and diabetic retinopathy compared to placebo or active comparators, but did increase the risk of nausea, diarrhea and vomiting. Conclusions: Semaglutide has a better effect on glycaemic control and weight loss than other therapies. Nevertheless, semaglutide was associated with increased incidence of gastrointestinal-related disorders. Further large, multicenter randomized controlled clinical trials are still needed to obtain more robust evidence to better guide clinical treatment decisions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13098-023-01195-7

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Risk of bias summary: review authors’ judgements about each risk of bias item for each included study
Fig. 1 Risk of bias summary: review authors’ judgements about each risk of bias item for each included studyCC BY · PubMed Central
Fig. 2 Mean difference of change in HbA1c (%) between semaglutide and placebo
Fig. 2 Mean difference of change in HbA1c (%) between semaglutide and placeboCC BY · PubMed Central
Fig. 3 Mean difference of change in HbA1c (%) between semaglutide and active comparator
Fig. 3 Mean difference of change in HbA1c (%) between semaglutide and active comparatorCC BY · PubMed Central
Fig. 4 Mean difference of change in body weight (kg) between Semaglutide and placebo
Fig. 4 Mean difference of change in body weight (kg) between Semaglutide and placeboCC BY · PubMed Central
Fig. 5 Mean difference of change in body weight (kg) between semaglutide and active comparator
Fig. 5 Mean difference of change in body weight (kg) between semaglutide and active comparatorCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Cited by

See all 28

Metadata

Authors
Hu, S., Su, X., & Fan, G.
Affiliations
  • Shanghai Jiao Tong University (CN)
  • Xiamen Maternal and Child Health Hospital (CN)
Corresponding author
Fan, Guorong
Venue
Diabetology & Metabolic Syndrome
Published
2023-10-28
Volume
15
Issue
1
Pages
218-218
ISSN
1758-5996 (ISSN-L)
OpenAlex
W4387996786
Cited by
28
References
60
Citations by year
2026: 4 · 2025: 13 · 2024: 11
FWCI
1.01
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetology & Metabolic Syndrome (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • the Research Fund for Clinical Pharmacy of China International Medical Foundation (Z-2021-46-2101)
  • National Natural Science Foundation of China (81973289)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
semaglutide, type 2 diabetes, subcutaneous administration, glycemic control, HbA1c, weight loss, blood pressure, adverse events, gastrointestinal adverse effects, nausea, acute pancreatitis, diabetic retinopathy, hypoglycemia, GLP-1 receptor agonists, tolerability, dose comparison

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis. https://app.cochat.ai/papers/10.1186/s13098-023-01195-7
The paper
Hu, S., Su, X., & Fan, G. (2023). Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis. Diabetology & Metabolic Syndrome. https://doi.org/10.1186/s13098-023-01195-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.